Trials / Recruiting
RecruitingNCT05632861
HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)
Efficacy and Safety of HuHuangLianzonggan Capsule in Subjects With Nonalcoholic steatoHEPAtitis: a Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 tRial(HHL-HEPAR)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 76 (estimated)
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety and the best effective dose of HuHuangLianzonggan capsule in subjects with nonalcoholic steatohepatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HuHuangLianzonggan capsule | HuHuangLianzonggan capsule, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks |
| DRUG | HuHuangLianzonggan capsule placebo | HuHuangLianzonggan capsule placebo, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks |
Timeline
- Start date
- 2023-02-21
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2022-12-01
- Last updated
- 2024-08-29
Locations
20 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05632861. Inclusion in this directory is not an endorsement.